Evommune Inc. shares plunged sharply in after-hours trading following the release of top-line Phase 2b data for EVO756 targeting moderate-to-severe atopic dermatitis. The stock fell 27.4% to $9.50 in after-hours trade, a move that came after the company had flagged this AD readout as a major clinical milestone for September 2026.
Investors reacted negatively to the topline announcement, extending a period of weak sentiment that began earlier this year when EVO756 failed in a separate indication. In June 2026, the candidate did not meet the primary endpoint in a Phase 2b study for chronic spontaneous urticaria - specifically, mean change in Urticaria Activity Score at 12 weeks - at any dose tested. Following that outcome, Evommune ceased development of EVO756 in CSU.
The June CSU setback had already triggered increased investor caution. Research firm William Blair downgraded the company to Market Perform after the CSU data were released, and a series of insider stock sales by senior executives in the weeks surrounding that failure further contributed to investor unease ahead of the AD readout.
Market context did little to dampen the EVMN decline. On the same trading day, the broader U.S. equity indices were muted - the S&P 500 was essentially flat, the Dow Jones Industrial Average was marginally lower, and the Nasdaq was little changed - indicating that the sharp selling in Evommune stock was driven by company-specific developments rather than a broad market move.
Peers in the clinical-stage inflammatory disease space, including companies such as Aclaris Therapeutics and Upstream Bio, did not register a comparable sell-off tied to this catalyst, underscoring that the reaction was isolated to Evommune. After-hours trading volume in EVMN was elevated versus recent sessions, consistent with the binary nature of a clinical readout event.
The new after-hours price of $9.50 sits below Evommunes prior 52-week low of $10.47, a technical breach that may prompt market participants to reassess the remaining value drivers in the companys pipeline. With EVO756 now carrying additional uncertainty following disappointing AD data and the earlier CSU failure, attention will likely refocus on other programs such as EVO756 in migraine prophylaxis and EVO301 - described as an IL-18 binding protein fusion protein in atopic dermatitis - as the principal potential sources of long-term value. Top-line data for EVO756 in migraine are not expected until 2027.
Takeaway: The after-hours sell-off in Evommune reflects investor disappointment with the topline Phase 2b AD readout for EVO756, compounded by a prior failed CSU study and insider sales. The stock now trades below its previous 52-week low, and the remaining pipeline programs have become focal points for assessing the companys prospective value.